Efficacy and safety of combined GnRH-a, hysteroscopic surgery, and LNG-IUS for adenomyosis with suboptimal HIFU ablation: a retrospective study

Peng Y, Yan Peng, Zhang N, Ning Zhang, Dai Y, Yu Dai, YUN LONG, Long Y, Guiyuan Yu, Yu G, Yue J, Junhong Yue, Jinyun Chen, Chen J, Ping Jin, Jin P
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · vol. 43(1) , pp. 2706037 · doi:10.1080/02656736.2026.2706037 · PMID:42533292 · W7171798773
article OA: gold public-domain-us
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-01 ⓘ

The sequential regimen of GnRH-a, hysteroscopic surgery, and LNG-IUS insertion effectively reduced pain and menstrual blood volume in adenomyosis patients with suboptimal HIFU ablation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To evaluate the safety and efficacy of sequential combination therapy comprising gonadotropin-releasing hormone agonist (GnRH-a), hysteroscopic surgery (residual lesion resection plus endometrial ablation), and levonorgestrel-releasing intrauterine system (LNG-IUS) insertion in patients with adenomyosis who exhibited suboptimal response to high-intensity focused ultrasound (HIFU) ablation (non-perfused volume (NPV) ratio < 50%). METHODS: This retrospective study enrolled 71 patients with adenomyosis who underwent HIFU ablation with an NPV ratio < 50% and subsequently received three doses of GnRH-a, followed by hysteroscopic surgery (residual lesion resection plus endometrial ablation) with concurrent LNG-IUS insertion (HIFU-GHL regimen). All patients completed a minimum follow-up of 24 months. Clinical efficacy was assessed using the visual analogue scale (VAS) for dysmenorrhea and the sensation quantity scale (SQS) for menstrual blood volume at baseline and at 6, 12, 18, and 24 months post-treatment. RESULTS: The median follow-up duration was 39 months (IQR: 29-53 months). The median NPV ratio following HIFU ablation was 22.2% (IQR: 12.0%-36.2%). Compared with baseline, significant reductions in both VAS and SQS scores were observed at all post-treatment time points (all p  0.05). Only two patients (2.8%) required re-intervention for recurrent dysmenorrhea. CONCLUSIONS: The sequential regimen of GnRH-a, hysteroscopic surgery (lesion resection plus endometrial ablation), and LNG-IUS insertion is a safe and effective uterine-preserving salvage strategy for adenomyosis patients with suboptimal HIFU ablation (NPV ratio < 50%). Prospective randomized trials with extended follow-up are warranted to validate these findings.

My notes (saved in your browser only)

MeSH descriptors

Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Gonadotropin-Releasing Hormone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (21)

SciLite annotations

chemicals 1
levonorgestrel

Source provenance

europepmc
last seen: 2026-08-16T06:08:05.154520+00:00
openalex
last seen: 2026-08-16T06:01:38.144443+00:00
pubmed
last seen: 2026-08-16T06:03:13.912897+00:00
scilite
last seen: 2026-08-09T09:47:33.675890+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine